The health, economic and social burden of dementia and neurodegenerative diseases is huge. 1 in 3 people will develop dementia, costing the UK £30 billion annually (Dementia UK report). Social inequalities and co-existing medical conditions worsen dementia risk and long-term outcomes. The Neurodegenerative Disease and Dementia (NDD) theme will discover and develop, launch new diagnostics, biomarkers and treatments. We will widen patient involvement, build research capacity and maximize impact through experimental medicine studies and clinical trials that accommodate the variability of these diseases, co-existing medical conditions, and promote inclusion of under-served groups.
Our work encompasses the study of common NDDs such as Alzheimer’s disease, Parkinson’s disease, Lewy Body Dementia and Vascular Dementia, as well as rarer disorders (Huntington’s disease, Frontotemporal dementias and Progressive Supranuclear Palsy). Our research impact is complemented by training and capacity development, with many PhD students, new Academic Clinical Lectureships and partnerships with other Universities and industry.
NDD research is aligned to the 2019 NHS Long Term Plan, which aims to improve dementia care, with a cure for dementia now a Government priority. We share the public’s priorities of improved diagnostics, treatment and disease prevention.
A synergistic core for human brain evolution and cognition
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy
In vivo 18F-flortaucipir PET does not accurately support the staging of progressive supranuclear palsy
Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson’s Disease to the Clinic: The Investigator’s Perspective
Altered network stability in progressive supranuclear palsy